Docetaxel and Trastuzumab therapy or maximal androgen blockade for patients with recurrent and/or metastatic salivary grand carcinoma - Docetaxel and Trastuzumab therapy or MAB for patients with recurrent and/or metastatic salivary grand carcinoma

International University of Health and Welfare Mita Hospital0 个研究点目标入组 30 人开始时间: 2012年12月3日最近更新: 2023年10月17日

适应症

试验速览

•<Docetaxel and Trastuzumab> Prior docetaxel or trastuzumab treatment was not allowed. The cumulative dose of anthracycline derivatives would not exceed 360 mg/m2 (converted into the dose of doxorubicin). Other exclusion criteria included , uncontrolled concomitant disease, active concomitant malignancy, a history of myocardial infarction or clinically important cardiovascular disease, a left ventricular ejection fraction (LVEF) less than 50% or below the upper limit of normal, New York Heart Association functional classification II to IV, suspected infection with fever, motor paralysis or peripheral neuropathy; pleural or pericardial effusion that required treatment, symptomatic brain metastasis, edema of grade 2 or higher, interstitial pneumonia or lung fibrosis, or allergy to polysorbate 80, pregnant women or women who might be pregnant. <MAB> Prior Bicalutamide or leuprorelin acetate treatment was not allowed. Other exclusion criteria included , uncontrolled concomitant disease, active concomitant malignancy, suspected infection with fever, motor paralysis or peripheral neuropathy; pleural or pericardial effusion that required treatment, edema of grade 2 or higher, interstitial pneumonia or lung fibrosis, pregnant women or women who might be pregnant or Physician judged improper to entry this trial.

发起方

International University of Health and Welfare Mita Hospital